In a report published Wednesday, Stifel analyst Stephen Willey reiterated a Buy rating on MacroGenics MGNX, but lowered the price target from $53.00 to $51.00.
In the report, Stifel noted, “The strategic shift in P3 margetuximab development shouldn't materially-impact commercialization timelines and ultimately expands the addressable market opportunity into a larger number of high-expressing HER2+ refractory metastatic breast cancer (mBCA) patients. The continued expansion of the MGA271 development program and the incremental disclosure of a CD19-targeting DART (MGD011) are incremental positives. Specific data timelines remain elusive but we'd anticipate a number of significant disclosures throughout FY15. Target to $51 (previously $53) on margetuximab estimate adjustments. Remains a core small cap name.”
MacroGenics closed on Tuesday at $21.15.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in